NCT04861194Recruiting
EREctile Function Preservation for Prostate Cancer Radiation Therapy (ERECT)
EREctile Function Preservation for Prostate Cancer Radiation Therapy (ERECT); a Prospective Phase II Trial
Source: ClinicalTrials.gov · Last updated 5 Mar 2026
Brief summary (registry, in English)
Single-arm phase II trial of 70 men with low- or intermediate-risk prostate cancer receiving magnetic resonance guided adaptive radiotherapy (MRgRT) in 5 fractions of 7.25 Gy, additionally sparing the neurovascular bundles, the internal pudendal arteries, the corpora cavernosa, and the penile bulb for erectile function preservation.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 22 Apr 2021
- Start date
- Jul 2021
- Primary completion date
- Aug 2027
- Lead sponsor
- UMC Utrecht
- Diseases
- Prostate cancer
- NCT number
- NCT04861194
What you commit to
- Study type: Interventional
- Planned participants: 70
- From Jul 2021 to the primary completion date, Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of (neo-)adjuvant androgen deprivation therapy
- Previous pelvic irradiation or radical prostatectomy
Other illness
- Clinical evidence of metastatic disease
Lab values
- High-risk prostate cancer according to NCCN risk categories (T3a or Gleason score 8-10 or PSA \>20 µg/L)
Other
- Patients with "bulky" iT3 tumor diagnosis
- Patients who are unable to undergo MRI
- Patients who are incompetent to sign written informed consent
Who the study is looking for
- Age ≥18 years
- Histologically proven adenocarcinoma of the prostate
- Low-risk or intermediate-risk prostate cancer according to NCCN risk categories (low risk: T1c-T2a, Gleason score ≤6, and PSA \<10 µg/L; intermediate risk: T2b-T2c or Gleason score 7 or PSA 10-20 µg/L)
- Patients with pT1a/b tumor diagnosis after transurethral resection of the prostate (TURP)
- Domain score of 17-25 on the International Index of Erectile Function-5 (IIEF-5) questionnaire
- Karnofsky score of 70-100
- Written informed consent
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Medical Center Utrecht Coordinator of this site? Confirm its status | Utrecht | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.